Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

37.28
Delayed Data
As of Nov 22
 0.00 / 0.00%
Today’s Change
29.39
Today|||52-Week Range
45.87
-2.28%
Year-to-Date
Wealthsource Partners, Llc Buys iShares 7-10 Year Treasury Bond ETF, iShares Edge MSC...
Nov 20 / GuruFocus News - Paid Partner Content
Hikma: chicken in the basket
Nov 09 / FT.com - Paid Partner Content
Theravance Shares Rise on Approval of Glaxo's COPD Therapy
Nov 17 / Zacks.com - Paid Partner Content
CVS Health holds deal talks with Aetna
Oct 26 / FT.com - Paid Partner Content
Theravance (TBPH) Submits NDA for COPD Candidate Revefenacin
Nov 14 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close37.28
Today’s open37.11
Day’s range36.99 - 37.76
Volume3,324,696
Average volume (3 months)6,601,309
Market cap$20.0B
Dividend yield--
Data as of 4:00pm ET, 11/22/2017

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)-6.97%
Earnings growth (next 5 years)+3.69%
Revenue growth (last year)+17.44%
P/E ratio22.7
Price/Sales1.79
Price/Book1.80

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...0.000.00%
PRGOPerrigo Company PLC0.000.00%
JAZZJazz Pharmaceuticals...0.000.00%
ALNYAlnylam Pharmaceutic...0.000.00%
Data as of 4:02pm ET, 11/22/2017

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)$1.41
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Director
Heather M. Bresch
President &
Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts